Crystalys Therapeutics

Crystalys Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on transforming the treatment of gout — a disease that affects an estimated 10 million Americans yet remains poorly served by existing therapies. The company's lead candidate, dotinurad, is a next-generation URAT1 inhibitor that addresses difficult-to-treat and refractory gout cases that cannot be adequately managed with generic allopurinol. Crystalys launched in September 2025 with a $205 million Series A financing round and is currently conducting Phase 2 clinical trials, with first patients dosed in May 2026. The company was founded by an experienced team with deep background in uric acid biology and URAT1 inhibitor mechanisms.